Comparison between low and high radioactive iodine (131I) reablation dose in patients with papillary thyroid cancer
AIMThe aim of this study was to assess ablation outcome after a second ablation dose and compare the ablation rate after low and high reablation doses of iodine-131 (I) after failure of the first ablation with 3700 MBq. PATIENTS AND METHODSThe study included 81 patients with papillary thyroid cancer...
Gespeichert in:
| Veröffentlicht in: | Nuclear medicine communications 2015-02, Vol.36 (2), p.114-119 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 119 |
|---|---|
| container_issue | 2 |
| container_start_page | 114 |
| container_title | Nuclear medicine communications |
| container_volume | 36 |
| creator | M. El-Refaei, Sherif W. Yassin, Shereen Salman, Khaled Al Munshy, Tarek Al-Ezzi, Manal M. Al-Sayed, Yasser Abd Elkareem Husseni, Maha |
| description | AIMThe aim of this study was to assess ablation outcome after a second ablation dose and compare the ablation rate after low and high reablation doses of iodine-131 (I) after failure of the first ablation with 3700 MBq.
PATIENTS AND METHODSThe study included 81 patients with papillary thyroid cancer; they failed to achieve complete ablation after a first ablative dose of 3700 MBq. Their first follow-up I whole-body scan carried out 6–9 months after ablation showed small residual functioning tissue in the thyroid bed, with no functioning metastases. This is associated with unsuppressed serum thyroglobulin level (Tg) higher than 2 ng/ml. The patients received a second ablation dose, which was low (1110 MBq) in 37 patients and high in the remaining 44 patients (2960 MBq in 36 patients and 3700 MBq in eight patients). A whole-body scan and Tg level assessment were carried out 6–9 months later. The criteria for complete ablation included absence of residual functioning thyroid tissue and a Tg level lower than 2 ng/ml.
RESULTSThe overall successful complete ablation rate after the second reablation dose was 75%. This was achieved in 27 of 37 patients (73%) who received a low reablation dose and in 34 of 44 patients (77%) who received a high reablation dose; no statistically significant difference was found between the two groups (P>0.05).
CONCLUSIONIn patients with papillary thyroid cancer who failed to achieve complete ablation after the first ablation dose of 3700 MBq, the overall complete ablation rate after both a low and a high second I dose was 75%, with no statistically significant difference in ablation rate between low (1110 MBq) and high (2960 and 3700 MBq) doses (73 and 77%, respectively). |
| doi_str_mv | 10.1097/MNM.0000000000000233 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1639496136</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1639496136</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4263-a9372156f7e6484380da93236d30f6e3449895e0305f73bcdaf10f37f77a69233</originalsourceid><addsrcrecordid>eNp9kE1v2zAMhoWhxZql-wdDoWN2cCuZsmQfi2AfAZLusp4NxaJnrY7lSsqM_PtqSFoUPZQXguT7ksRDyBfOrjmr1M3mbnPNXkcO8IHMuFCQFTIvz8iMcQEZSJAX5FMIf5OmBKk-kou8gIIJyWYkLN1u1N4GN9AtxglxoL2bqB4M7eyfjnptrNNNtP-QWmfsgHTBga--Uo962-tok9O4kKYDHVOJQwx0srFL1Wj7XvsDjd3BO2too4cG_SU5b3Uf8PMpz8n992-_lz-z9a8fq-XtOmtELiHTFaicF7JVKEUpoGQmtXKQBlgrEYSoyqpABqxoFWwbo1vOWlCtUlpWicacLI57R-8e9xhivbOhwfTSgG4fai6hEpXkidCciKO08S4Ej209ertLr9ec1f9x1wl3_RZ3sl2dLuy3OzQvpme-SVAeBZPrI_rw0O8n9HWHuo_d-7ufAN0NizQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1639496136</pqid></control><display><type>article</type><title>Comparison between low and high radioactive iodine (131I) reablation dose in patients with papillary thyroid cancer</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>M. El-Refaei, Sherif ; W. Yassin, Shereen ; Salman, Khaled ; Al Munshy, Tarek ; Al-Ezzi, Manal ; M. Al-Sayed, Yasser ; Abd Elkareem Husseni, Maha</creator><creatorcontrib>M. El-Refaei, Sherif ; W. Yassin, Shereen ; Salman, Khaled ; Al Munshy, Tarek ; Al-Ezzi, Manal ; M. Al-Sayed, Yasser ; Abd Elkareem Husseni, Maha</creatorcontrib><description>AIMThe aim of this study was to assess ablation outcome after a second ablation dose and compare the ablation rate after low and high reablation doses of iodine-131 (I) after failure of the first ablation with 3700 MBq.
PATIENTS AND METHODSThe study included 81 patients with papillary thyroid cancer; they failed to achieve complete ablation after a first ablative dose of 3700 MBq. Their first follow-up I whole-body scan carried out 6–9 months after ablation showed small residual functioning tissue in the thyroid bed, with no functioning metastases. This is associated with unsuppressed serum thyroglobulin level (Tg) higher than 2 ng/ml. The patients received a second ablation dose, which was low (1110 MBq) in 37 patients and high in the remaining 44 patients (2960 MBq in 36 patients and 3700 MBq in eight patients). A whole-body scan and Tg level assessment were carried out 6–9 months later. The criteria for complete ablation included absence of residual functioning thyroid tissue and a Tg level lower than 2 ng/ml.
RESULTSThe overall successful complete ablation rate after the second reablation dose was 75%. This was achieved in 27 of 37 patients (73%) who received a low reablation dose and in 34 of 44 patients (77%) who received a high reablation dose; no statistically significant difference was found between the two groups (P>0.05).
CONCLUSIONIn patients with papillary thyroid cancer who failed to achieve complete ablation after the first ablation dose of 3700 MBq, the overall complete ablation rate after both a low and a high second I dose was 75%, with no statistically significant difference in ablation rate between low (1110 MBq) and high (2960 and 3700 MBq) doses (73 and 77%, respectively).</description><identifier>ISSN: 0143-3636</identifier><identifier>EISSN: 1473-5628</identifier><identifier>DOI: 10.1097/MNM.0000000000000233</identifier><identifier>PMID: 25350460</identifier><language>eng</language><publisher>England: Wolters Kluwer Health | Lippincott Williams & Wilkins</publisher><subject>Ablation Techniques - methods ; Adult ; Aged ; Carcinoma - blood ; Carcinoma - diagnosis ; Carcinoma - therapy ; Carcinoma, Papillary ; Female ; Humans ; Iodine Radioisotopes - therapeutic use ; Male ; Middle Aged ; Radiation Dosage ; Radiotherapy Dosage ; Thyroglobulin - blood ; Thyroid Cancer, Papillary ; Thyroid Neoplasms - blood ; Thyroid Neoplasms - diagnosis ; Thyroid Neoplasms - therapy ; Treatment Outcome ; Whole Body Imaging ; Young Adult</subject><ispartof>Nuclear medicine communications, 2015-02, Vol.36 (2), p.114-119</ispartof><rights>2015 Wolters Kluwer Health | Lippincott Williams & Wilkins</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4263-a9372156f7e6484380da93236d30f6e3449895e0305f73bcdaf10f37f77a69233</citedby><cites>FETCH-LOGICAL-c4263-a9372156f7e6484380da93236d30f6e3449895e0305f73bcdaf10f37f77a69233</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25350460$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>M. El-Refaei, Sherif</creatorcontrib><creatorcontrib>W. Yassin, Shereen</creatorcontrib><creatorcontrib>Salman, Khaled</creatorcontrib><creatorcontrib>Al Munshy, Tarek</creatorcontrib><creatorcontrib>Al-Ezzi, Manal</creatorcontrib><creatorcontrib>M. Al-Sayed, Yasser</creatorcontrib><creatorcontrib>Abd Elkareem Husseni, Maha</creatorcontrib><title>Comparison between low and high radioactive iodine (131I) reablation dose in patients with papillary thyroid cancer</title><title>Nuclear medicine communications</title><addtitle>Nucl Med Commun</addtitle><description>AIMThe aim of this study was to assess ablation outcome after a second ablation dose and compare the ablation rate after low and high reablation doses of iodine-131 (I) after failure of the first ablation with 3700 MBq.
PATIENTS AND METHODSThe study included 81 patients with papillary thyroid cancer; they failed to achieve complete ablation after a first ablative dose of 3700 MBq. Their first follow-up I whole-body scan carried out 6–9 months after ablation showed small residual functioning tissue in the thyroid bed, with no functioning metastases. This is associated with unsuppressed serum thyroglobulin level (Tg) higher than 2 ng/ml. The patients received a second ablation dose, which was low (1110 MBq) in 37 patients and high in the remaining 44 patients (2960 MBq in 36 patients and 3700 MBq in eight patients). A whole-body scan and Tg level assessment were carried out 6–9 months later. The criteria for complete ablation included absence of residual functioning thyroid tissue and a Tg level lower than 2 ng/ml.
RESULTSThe overall successful complete ablation rate after the second reablation dose was 75%. This was achieved in 27 of 37 patients (73%) who received a low reablation dose and in 34 of 44 patients (77%) who received a high reablation dose; no statistically significant difference was found between the two groups (P>0.05).
CONCLUSIONIn patients with papillary thyroid cancer who failed to achieve complete ablation after the first ablation dose of 3700 MBq, the overall complete ablation rate after both a low and a high second I dose was 75%, with no statistically significant difference in ablation rate between low (1110 MBq) and high (2960 and 3700 MBq) doses (73 and 77%, respectively).</description><subject>Ablation Techniques - methods</subject><subject>Adult</subject><subject>Aged</subject><subject>Carcinoma - blood</subject><subject>Carcinoma - diagnosis</subject><subject>Carcinoma - therapy</subject><subject>Carcinoma, Papillary</subject><subject>Female</subject><subject>Humans</subject><subject>Iodine Radioisotopes - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Radiation Dosage</subject><subject>Radiotherapy Dosage</subject><subject>Thyroglobulin - blood</subject><subject>Thyroid Cancer, Papillary</subject><subject>Thyroid Neoplasms - blood</subject><subject>Thyroid Neoplasms - diagnosis</subject><subject>Thyroid Neoplasms - therapy</subject><subject>Treatment Outcome</subject><subject>Whole Body Imaging</subject><subject>Young Adult</subject><issn>0143-3636</issn><issn>1473-5628</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1v2zAMhoWhxZql-wdDoWN2cCuZsmQfi2AfAZLusp4NxaJnrY7lSsqM_PtqSFoUPZQXguT7ksRDyBfOrjmr1M3mbnPNXkcO8IHMuFCQFTIvz8iMcQEZSJAX5FMIf5OmBKk-kou8gIIJyWYkLN1u1N4GN9AtxglxoL2bqB4M7eyfjnptrNNNtP-QWmfsgHTBga--Uo962-tok9O4kKYDHVOJQwx0srFL1Wj7XvsDjd3BO2too4cG_SU5b3Uf8PMpz8n992-_lz-z9a8fq-XtOmtELiHTFaicF7JVKEUpoGQmtXKQBlgrEYSoyqpABqxoFWwbo1vOWlCtUlpWicacLI57R-8e9xhivbOhwfTSgG4fai6hEpXkidCciKO08S4Ej209ertLr9ec1f9x1wl3_RZ3sl2dLuy3OzQvpme-SVAeBZPrI_rw0O8n9HWHuo_d-7ufAN0NizQ</recordid><startdate>201502</startdate><enddate>201502</enddate><creator>M. El-Refaei, Sherif</creator><creator>W. Yassin, Shereen</creator><creator>Salman, Khaled</creator><creator>Al Munshy, Tarek</creator><creator>Al-Ezzi, Manal</creator><creator>M. Al-Sayed, Yasser</creator><creator>Abd Elkareem Husseni, Maha</creator><general>Wolters Kluwer Health | Lippincott Williams & Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201502</creationdate><title>Comparison between low and high radioactive iodine (131I) reablation dose in patients with papillary thyroid cancer</title><author>M. El-Refaei, Sherif ; W. Yassin, Shereen ; Salman, Khaled ; Al Munshy, Tarek ; Al-Ezzi, Manal ; M. Al-Sayed, Yasser ; Abd Elkareem Husseni, Maha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4263-a9372156f7e6484380da93236d30f6e3449895e0305f73bcdaf10f37f77a69233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Ablation Techniques - methods</topic><topic>Adult</topic><topic>Aged</topic><topic>Carcinoma - blood</topic><topic>Carcinoma - diagnosis</topic><topic>Carcinoma - therapy</topic><topic>Carcinoma, Papillary</topic><topic>Female</topic><topic>Humans</topic><topic>Iodine Radioisotopes - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Radiation Dosage</topic><topic>Radiotherapy Dosage</topic><topic>Thyroglobulin - blood</topic><topic>Thyroid Cancer, Papillary</topic><topic>Thyroid Neoplasms - blood</topic><topic>Thyroid Neoplasms - diagnosis</topic><topic>Thyroid Neoplasms - therapy</topic><topic>Treatment Outcome</topic><topic>Whole Body Imaging</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>M. El-Refaei, Sherif</creatorcontrib><creatorcontrib>W. Yassin, Shereen</creatorcontrib><creatorcontrib>Salman, Khaled</creatorcontrib><creatorcontrib>Al Munshy, Tarek</creatorcontrib><creatorcontrib>Al-Ezzi, Manal</creatorcontrib><creatorcontrib>M. Al-Sayed, Yasser</creatorcontrib><creatorcontrib>Abd Elkareem Husseni, Maha</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Nuclear medicine communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>M. El-Refaei, Sherif</au><au>W. Yassin, Shereen</au><au>Salman, Khaled</au><au>Al Munshy, Tarek</au><au>Al-Ezzi, Manal</au><au>M. Al-Sayed, Yasser</au><au>Abd Elkareem Husseni, Maha</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison between low and high radioactive iodine (131I) reablation dose in patients with papillary thyroid cancer</atitle><jtitle>Nuclear medicine communications</jtitle><addtitle>Nucl Med Commun</addtitle><date>2015-02</date><risdate>2015</risdate><volume>36</volume><issue>2</issue><spage>114</spage><epage>119</epage><pages>114-119</pages><issn>0143-3636</issn><eissn>1473-5628</eissn><abstract>AIMThe aim of this study was to assess ablation outcome after a second ablation dose and compare the ablation rate after low and high reablation doses of iodine-131 (I) after failure of the first ablation with 3700 MBq.
PATIENTS AND METHODSThe study included 81 patients with papillary thyroid cancer; they failed to achieve complete ablation after a first ablative dose of 3700 MBq. Their first follow-up I whole-body scan carried out 6–9 months after ablation showed small residual functioning tissue in the thyroid bed, with no functioning metastases. This is associated with unsuppressed serum thyroglobulin level (Tg) higher than 2 ng/ml. The patients received a second ablation dose, which was low (1110 MBq) in 37 patients and high in the remaining 44 patients (2960 MBq in 36 patients and 3700 MBq in eight patients). A whole-body scan and Tg level assessment were carried out 6–9 months later. The criteria for complete ablation included absence of residual functioning thyroid tissue and a Tg level lower than 2 ng/ml.
RESULTSThe overall successful complete ablation rate after the second reablation dose was 75%. This was achieved in 27 of 37 patients (73%) who received a low reablation dose and in 34 of 44 patients (77%) who received a high reablation dose; no statistically significant difference was found between the two groups (P>0.05).
CONCLUSIONIn patients with papillary thyroid cancer who failed to achieve complete ablation after the first ablation dose of 3700 MBq, the overall complete ablation rate after both a low and a high second I dose was 75%, with no statistically significant difference in ablation rate between low (1110 MBq) and high (2960 and 3700 MBq) doses (73 and 77%, respectively).</abstract><cop>England</cop><pub>Wolters Kluwer Health | Lippincott Williams & Wilkins</pub><pmid>25350460</pmid><doi>10.1097/MNM.0000000000000233</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0143-3636 |
| ispartof | Nuclear medicine communications, 2015-02, Vol.36 (2), p.114-119 |
| issn | 0143-3636 1473-5628 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1639496136 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Ablation Techniques - methods Adult Aged Carcinoma - blood Carcinoma - diagnosis Carcinoma - therapy Carcinoma, Papillary Female Humans Iodine Radioisotopes - therapeutic use Male Middle Aged Radiation Dosage Radiotherapy Dosage Thyroglobulin - blood Thyroid Cancer, Papillary Thyroid Neoplasms - blood Thyroid Neoplasms - diagnosis Thyroid Neoplasms - therapy Treatment Outcome Whole Body Imaging Young Adult |
| title | Comparison between low and high radioactive iodine (131I) reablation dose in patients with papillary thyroid cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T20%3A14%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20between%20low%20and%20high%20radioactive%20iodine%20(131I)%20reablation%20dose%20in%20patients%20with%20papillary%20thyroid%20cancer&rft.jtitle=Nuclear%20medicine%20communications&rft.au=M.%20El-Refaei,%20Sherif&rft.date=2015-02&rft.volume=36&rft.issue=2&rft.spage=114&rft.epage=119&rft.pages=114-119&rft.issn=0143-3636&rft.eissn=1473-5628&rft_id=info:doi/10.1097/MNM.0000000000000233&rft_dat=%3Cproquest_cross%3E1639496136%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1639496136&rft_id=info:pmid/25350460&rfr_iscdi=true |